WO2018095430A1 - Capsule molle de fullerène et son procédé de préparation - Google Patents

Capsule molle de fullerène et son procédé de préparation Download PDF

Info

Publication number
WO2018095430A1
WO2018095430A1 PCT/CN2017/113120 CN2017113120W WO2018095430A1 WO 2018095430 A1 WO2018095430 A1 WO 2018095430A1 CN 2017113120 W CN2017113120 W CN 2017113120W WO 2018095430 A1 WO2018095430 A1 WO 2018095430A1
Authority
WO
WIPO (PCT)
Prior art keywords
soft capsule
fullerene
capsule
oil phase
liquid
Prior art date
Application number
PCT/CN2017/113120
Other languages
English (en)
Chinese (zh)
Inventor
刘伟
白雪铠
钟俭
甄明明
李慧
许哲
Original Assignee
北京福纳康生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京福纳康生物技术有限公司 filed Critical 北京福纳康生物技术有限公司
Publication of WO2018095430A1 publication Critical patent/WO2018095430A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Definitions

  • the invention relates to the field of soft capsules and preparation, in particular to a fullerene soft capsule and a preparation method thereof.
  • the soft capsule packaging can quantitatively inject and encapsulate the oily functional substance, the functional substance solution or the functional substance suspension, the paste and even the functional substance into the adhesive film to form a sealed capsule of different sizes and shapes. It has excellent isolation light, oxygen function and good visual effect. It has high bioavailability, accurate content, good uniformity and beautiful appearance. It is very suitable for packaging of medicines and health products.
  • Fullerene is a family of fullerenes represented by C60. With its unique shape and good properties, it has opened up a new research direction in physics, chemistry and materials science. Similar to benzene, which is very common in organic chemistry, fullerenes represented by C60 form the basis of a rich variety of organic compounds. After Kratzchimer and Hoffman first prepared a macroscopic amount of C60, scientists have experimentally prepared a large number of fullerene derivatives and extensively studied their properties, and the great application of developing such new substances. potential. Almost all of the unusual properties of new fullerene materials can be found in modern technology and industrial sectors, which is why people are so interested in fullerenes or buckyballs.
  • fullerene materials are multifaceted, including lubricants, catalysts, abrasives, high strength carbon fibers, semiconductors, nonlinear optics, superconducting materials, photoconductors, high energy batteries, fuels, sensors, molecular devices. And for medical imaging and treatment.
  • C60 fullerene is a strong antioxidant, its antioxidant power is 125 times that of vitamin C. In addition to anti-oxidation, C60 fullerene also has the function of scavenging free radicals and activating skin cells (prevention of decline). use. Since 1990, great progress has been made in the study of C60 fullerene in scavenging free radical function. Many scientific research results have confirmed that C60 fullerene is a strong free radical scavenging molecule, which can be said to be a very Strong antioxidants.
  • the object of the present invention is to solve the problems of poor stability and low bioavailability of the existing fullerene preparations, and to provide a fullerene soft capsule and a preparation method thereof.
  • a fullerene soft capsule comprising a soft capsule liquid and an soft capsule shell, the soft capsule liquid containing an active ingredient, an oil phase, an antioxidant; the active ingredient is fullerene; the soft capsule liquid
  • the mass ratio to the soft capsule shell is 1:5-5:1.
  • a fullerene soft capsule comprising a soft capsule liquid and an soft capsule shell, the soft capsule liquid containing an active ingredient, an oil phase, an antioxidant, an auxiliary; the active ingredient is fullerene; the soft capsule
  • the mass ratio of the drug solution to the soft capsule shell is 1:5-5:1.
  • the fullerene is C60, C70, C76 or Gd@C82; the mass of the fullerene and the oil phase is from 0.1 to 10 mg/ml.
  • the fullerene is C60.
  • the mass of the fullerene and the oil phase is from 0.5 to 5 mg/ml, and more preferably, the mass of the fullerene and the oil phase is from 4 to 5 mg/ml.
  • the oil phase is one or more of soybean oil, peanut oil, eucalyptus oil, and sesame oil.
  • Other edible oils such as rapeseed oil, sunflower oil, etc. can also be used as the oil phase.
  • the antioxidant comprises one or both of vitamin E acetate, butyl hydroxy anisole, and tert-butyl hydroquinone; and the mass volume of the antioxidant and the oil phase is 0.1-1 mg/ml. .
  • the antioxidant and the oil phase have a mass volume of from 0.1 to 0.4 mg/ml.
  • the antioxidant comprises vitamin E acetate and tert-butyl hydroquinone, wherein the concentration of vitamin E acetate and tert-butyl hydroquinone in the oil phase is 0.1-0.2 mg/ml. .
  • the concentration of the vitamin E acetate and the tert-butyl hydroquinone in the oil phase is 0.1 mg/ml.
  • the excipient is a colorant or flavoring agent.
  • composition of the soft capsule shell comprises medicinal dry gelatin, glycerin and water in a mass ratio of 30-40:20-30:30-50.
  • composition of the soft capsule shell further comprises one or more of iron trioxide, titanium dioxide, ethyl paraben, sorbitol liquid, sodium benzoate, and hydroxyethyl ester.
  • the composition of the soft capsule shell is medicinal dry gelatin, glycerin, iron trioxide, titanium dioxide, ethyl paraben, sorbitol liquid, water.
  • the soft capsule solution further comprises an emulsifier, the component of which is one or both of fatty acid sorbitan, stearic acid monoglyceride.
  • an emulsifier the component of which is one or both of fatty acid sorbitan, stearic acid monoglyceride.
  • the mass to volume ratio of the emulsifier to the oil phase is from 0.1 to 1 mg/ml.
  • the mass ratio of the soft capsule liquid to the soft capsule shell is 1:2-2:1; further optionally 1:1.5-1.5:1.
  • Another aspect of the invention is a method for preparing a fullerene soft capsule comprising the steps of:
  • the preparation of the fullerene oil solution into a soft capsule is advantageous for improving the stability of the fullerene oil solution, is convenient to carry, and is convenient to take, and at the same time, avoids the greasy feeling when the oil solution is taken, and has good practicability and innovation.
  • the capsule is encapsulated into the stomach after being encapsulated by the capsule shell, and the gastric juice first dissolves the capsule shell, and the fullerene vegetable oil is released, thereby reducing the decomposition time of the gastric juice to the fullerene vegetable oil, so that the intestinal tract can fully absorb the rich Resin vegetable oil increases the availability of the drug.
  • the capsule of the embodiment of the invention can be quantitatively administered, ensuring accurate dosage of the patient each time, improving patient comfort and enhancing patient compliance.
  • Soft capsule shell preparation a certain proportion of medicinal dry gelatin, glycerin, iron trioxide, titanium dioxide, paraben ethyl ester, sorbitol liquid, water amount, prepared according to conventional methods.
  • Preparation of soft capsule The soft capsule shell and the liquid medicine are placed in a pelletizing machine and then placed in a rolling machine for setting, and air-dried in a drying chamber at 38 ° C.
  • Example 9 Screening of each auxiliary material of soft capsule liquid
  • the above is the solubility of each fullerene at 25 °C.
  • Medicinal soybean oil and olive oil have higher solubility for fullerenes.
  • the diffusion rate of the drug is inversely proportional to the molecular weight. Therefore, the molecular weight of the drug increases, and the passive absorption through the cell is weakened.
  • the upper limit of the molecular weight of the oral drug is 500-750. Therefore, the fullerene C60 is selected as a drug molecule, which is more beneficial to the human body. absorb.
  • the solution is prepared by dissolving 5 mg of C60 olive oil per ml, prepared according to the method of Example 1) and a 250 ml beaker, and then adding 0.02% (0.2 mg/ml) of the antioxidant and stirring.
  • Uniform open placed in a 62 ° C incubator, sampling for 2 days interval to detect peroxide value, peroxide value according to ICH guidelines, the fourth general rule of the Chinese Pharmacopoeia 0713, 2303 and the use of oil physicochemical speedometer 30 (Shanghai thousand Mu Biotech Co., Ltd.) for testing.
  • the storage time of the liquid at 62 °C was obtained from the schaal heat-resistance test, and the expected storage time of the liquid at 25 °C was extrapolated according to the relationship between the temperature and the shelf life factor of the oil, that is, its expected shelf life. .
  • Oxidative inhibition of capsule fluid using a composite antioxidant (total amount 0.02%), a, tert-butyl hydroquinone 0.01% + vitamin E acetate 0.01%; b, tert-butyl hydroquinone 0.01 %+butylhydroxyanisole 0.01; c, tert-butyl hydroquinone 0.01%+ ⁇ -tocopherol 0.01%; d, vitamin E acetate 0.01%+butylhydroxyanisole 0.01; e, vitamin E acetate Ester 0.01% + ⁇ -tocopherol 0.01%; f, butyl hydroxy anisole 0.01 + ⁇ -tocopherol 0.01%, of which 0.01% is 0.1 mg / ml.
  • the inhibitory effect of the composite antioxidant was better than that of the single-use butyl hydroquinone 0.01% + vitamin E acetate 0.01% composite antioxidant.
  • Example 11 screening of soft capsule shell material composition
  • the auxiliary materials are mixed into a gelatin solution according to the mass% of the shell material, and dissolved at 80 ° C. After the bubbles were allowed to stand at 60 ° C for 10 h, a gelatin colloid was obtained, and a soft capsule was obtained by a soft capsule mechanism. The percentage of each excipient mass is shown in Table 6-Table 9.
  • the prepared soft capsule (containing the liquid medicine containing 5 mg of C60 olive oil per ml, prepared according to the method of Example 1) was packaged in PTP, stored at 25 ° C, RH 60% for 6 months, and examined for content logistics. Out, whether the capsule is deformed and observed changes, the results are as follows:
  • the soft capsules of the composition described in Table 9 were stored at 25 ° C, RH 60% for 6 months without content, and the capsules were not deformed. After preparing the soft capsules for the capsule composition, the capsule disintegration time and water content were tested.
  • Soft capsule disintegration experiment 1 ml soft capsules were prepared and placed in a disintegration apparatus at 37 ° C ⁇ 0.5 ° C constant temperature, and the basket lifting time was 15 min.
  • A-f represents 6 parallel soft capsules at each experiment.
  • the prepared soft capsule can be completely disintegrated within 1 h, complies with the Pharmacopoeia regulations, and does not cause side effects to the body.
  • the water activity value of the capsule is still 0.55, and the water loss is slow, which is beneficial to the long-term storage of soft capsules.
  • Fullerene soft capsule capsule 50g fullerene C60, 10L olive oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 30 g fullerene C70, 10 L olive oil, 1 g tert-butyl hydroquinone and 1 g vitamin E acetate;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 20g fullerene C76, 20L olive oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 650mg fullerene Gd@C82, 10L olive oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 80g fullerene C60, 20L olive oil, 2g tert-butyl hydroquinone and 3g vitamin E acetate;
  • Fullerene soft capsule capsule 10kg medicinal dry gelatin, 6kg glycerin, 65g sorbitol sugar solution, 35g ferric oxide, 4g sweet citrus, 15g sodium benzoate and 7kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 40,000 0.5 ml fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 40g fullerene C60, 10L medicinal soybean oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 4kg amber gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g menthol, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 20,000 0.5 ml fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 30g fullerene C70, 10L medicinal soybean oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g titanium dioxide, 2g sweet citrus, 10g potassium sorbate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 40g fullerene C60, 10L flax oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 4kg succinized gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g iron trioxide, 2g aspartame, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 20,000 0.5 ml fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 650 mg fullerene Gd@C82, 10 L olive oil, 0.5 g tert-butyl hydroquinone and 1 g vitamin E acetate;
  • Fullerene soft capsule capsule 5kg medicinal dry gelatin, 3kg glycerin, 30g sorbitol sugar solution, 20g iron trioxide, 2g borneol, 11g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 12000 full-sized soft capsules of 0.8 ml size, and the specific operation method was the same as that of Example 1, except that the type and amount of the components were changed.
  • Fullerene soft capsule capsule 20g fullerene C76, 20L medicinal soybean oil, 2g tert-butyl hydroquinone and 2g vitamin E acetate;
  • Fullerene soft capsule capsule 10kg medicinal dry gelatin, 7kg glycerin, 30g sorbitol sugar solution, 10g sodium benzoate and 6.6kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 20,000 1 ml-sized fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 50g fullerene C60, 15L olive oil, 2g tert-butyl hydroquinone and 1g vitamin E acetate, 600g monoglyceride acid ester;
  • Fullerene soft capsule capsule 5kg medicinal dry gelatin, 2.8kg glycerin, 40g sorbitol sugar solution, 20g titanium dioxide, 10g hydroxyethyl ester and 4kg water;
  • the above materials were obtained by a capsule mechanism to obtain 22000 0.4 ml fullerene soft capsules.
  • the specific operation method was the same as in Example 1, and the antioxidant was added together with monoglyceryl stearic acid, and only the component types and amounts were changed.
  • the drug must pass through the biofilm to be lipophilic, and it must be dissolved in the gastrointestinal tract, and it needs sufficient hydrophilicity. Therefore, a pharmaceutically acceptable surfactant such as Span-80 or glyceryl monostearate is added to the capsule solution.
  • a pharmaceutically acceptable surfactant such as Span-80 or glyceryl monostearate is added to the capsule solution.
  • Diethylene glycol monoglyceride can enhance the hydrophilicity of the drug solution, is more conducive to drug absorption, and increases the bioavailability of the drug.
  • Fullerene soft capsule capsule 60g fullerene C60, 13L medicinal soybean oil, 1.5g tert-butyl hydroquinone and 1.5g vitamin E acetate;
  • Fullerene soft capsule capsule 6kg medicinal dry gelatin, 4kg glycerin, 30g sorbitol sugar solution, 20g iron trioxide, 2g aspartame, 10g potassium sorbate and 4kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 15,000 full-sized soft capsules of 0.6 ml size, and the specific operation method was the same as that of Example 1, except that the types and amounts of the components were changed.
  • Fullerene soft capsule capsule 40g fullerene C60, 10L peanut oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 4kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 60g fullerene C70, 30L olive oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 8kg amber gelatin, 5kg glycerin, 30g sorbitol sugar solution, 10g sodium benzoate and 7kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 50,000 full-alkene soft capsules of 0.6 ml size, and the specific operation method was the same as that of Example 1, except that the type and amount of the components were changed.
  • Fullerene soft capsule capsule 2.6 g fullerene Gd@C82, 40 L olive oil, 2 g tert-butyl hydroquinone and 2 g vitamin E acetate;
  • Fullerene soft capsule capsule 10kg medicinal dry gelatin, 7kg glycerin, 60g sorbitol sugar solution, 4g sweet citrus, 20g hydroxypropyl propyl ester and 8kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 40,000 1 ml fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 50g fullerene C60, 20L medicinal soybean oil, 1g tert-butyl hydroquinone and 1g vitamin E acetate;
  • Fullerene soft capsule capsule 9kg medicinal dry gelatin, 6kg glycerin, 50g sorbitol sugar solution, 30g ferric oxide, 4g sweet citrus, 20g sodium benzoate and 7kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 20,000 1 ml-sized fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 30 g fullerene C70, 20 L olive oil, 2 g tert-butyl hydroquinone and 1 g vitamin E acetate;
  • Fullerene soft capsule capsule 10kg medicinal dry gelatin, 5kg glycerin, 50g sorbitol sugar solution, 30g ferric oxide, 5g sweet citrus, 10g potassium sorbate and 8kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 40,000 0.5 ml fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 50 g fullerene C60, 10 L olive oil, 1 g tert-butyl hydroquinone and 1 g butyl hydroxyanisole;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 30 g fullerene C70, 10 L soybean oil, 1 g tert-butyl hydroquinone and 1 g butyl hydroxyanisole;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 20g fullerene C76, 20L flax oil, 1g tert-butyl hydroquinone and 1g butyl hydroxyanisole;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • Fullerene soft capsule capsule 650 mg fullerene Gd@C82, 10 L peanut oil, 1 g tert-butyl hydroquinone and 1 g butyl hydroxyanisole;
  • Fullerene soft capsule capsule 4kg medicinal dry gelatin, 2.8kg glycerin, 30g sorbitol sugar solution, 20g ferric oxide, 2g sweet citrus, 10g sodium benzoate and 3.2kg water;
  • Example 1 The above materials were obtained by a capsule mechanism to obtain 10,000 tablets of 1 ml-size fullerene soft capsules, and the specific operation method was the same as in Example 1, except that the component types and amounts were changed.
  • An embodiment of the present invention provides a fullerene soft capsule, comprising a soft capsule liquid and an soft capsule shell, wherein the soft capsule liquid contains an active ingredient, an oil phase, an antioxidant, and an auxiliary; the active ingredient is Fuller
  • the mass ratio of the soft capsule liquid to the soft capsule shell is 1:5-5:1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une capsule molle de fullerène comprenant un liquide médicamenteux de capsule molle et une coque de capsule molle, le liquide médicamenteux de capsule molle comprenant un principe actif, une phase huileuse, un antioxydant et des excipients ; le principe actif est un fullerène ; et le rapport en masse du liquide médicamenteux de capsule molle à la coque de capsule molle est de 1 : 5 à 5 : 1.
PCT/CN2017/113120 2016-11-25 2017-11-27 Capsule molle de fullerène et son procédé de préparation WO2018095430A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611055877.6A CN106491644A (zh) 2016-11-25 2016-11-25 一种富勒烯软胶囊及制备方法
CN2016110558776 2016-11-25

Publications (1)

Publication Number Publication Date
WO2018095430A1 true WO2018095430A1 (fr) 2018-05-31

Family

ID=58328857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/113120 WO2018095430A1 (fr) 2016-11-25 2017-11-27 Capsule molle de fullerène et son procédé de préparation

Country Status (2)

Country Link
CN (1) CN106491644A (fr)
WO (1) WO2018095430A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106491644A (zh) * 2016-11-25 2017-03-15 北京福纳康生物技术有限公司 一种富勒烯软胶囊及制备方法
CN107510050A (zh) * 2017-09-19 2017-12-26 太仓市林港农场专业合作社 一种蒜氨酸复方微胶囊及其制备方法
CN107596158A (zh) * 2017-09-19 2018-01-19 太仓市林港农场专业合作社 一种大蒜精油复方辅助降血脂软胶囊及其制备方法
CN109925322B (zh) * 2017-12-19 2021-11-26 中国科学院化学研究所 水溶性富勒烯结构在制备治疗胰腺疾病的药物中的应用
CN108497099A (zh) * 2018-03-27 2018-09-07 厦门福慈生物科技有限公司 富勒烯被用于制备成富勒烯微囊粉的用途
CN109349673B (zh) * 2018-10-22 2021-10-08 辽渔南极磷虾科技发展有限公司 一种南极磷虾油软胶囊囊皮、软胶囊及其制备方法
CN109288058A (zh) * 2018-12-05 2019-02-01 北京富乐喜科技有限公司 一种富勒烯增强正常细胞活性的保健品制剂及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753968A (zh) * 2003-01-27 2006-03-29 三菱商事株式会社 抗氧化组合物以及外用组合物
CN103705388A (zh) * 2013-12-19 2014-04-09 深圳市通产丽星股份有限公司 一种富勒烯胶囊及其应用
CN106491644A (zh) * 2016-11-25 2017-03-15 北京福纳康生物技术有限公司 一种富勒烯软胶囊及制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103211781B (zh) * 2013-03-21 2014-07-30 青岛正大海尔制药有限公司 依托泊苷软胶囊

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753968A (zh) * 2003-01-27 2006-03-29 三菱商事株式会社 抗氧化组合物以及外用组合物
CN103705388A (zh) * 2013-12-19 2014-04-09 深圳市通产丽星股份有限公司 一种富勒烯胶囊及其应用
CN106491644A (zh) * 2016-11-25 2017-03-15 北京福纳康生物技术有限公司 一种富勒烯软胶囊及制备方法

Also Published As

Publication number Publication date
CN106491644A (zh) 2017-03-15

Similar Documents

Publication Publication Date Title
WO2018095430A1 (fr) Capsule molle de fullerène et son procédé de préparation
Hsu et al. Clinical studies with curcumin
Wang et al. Enhanced oral bioavailability and anti-gout activity of [6]-shogaol-loaded solid lipid nanoparticles
TWI667044B (zh) 用於減少體重的皮下注射劑及其用途
CN109223725A (zh) 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
TW201114766A (en) Pharmaceutical composition for a hepatitis C viral protease inhibitor
CN101862293B (zh) 盐酸多西环素的油混悬液及其制备方法和应用
Sun et al. Gram-scale preparation of quercetin supramolecular nanoribbons for intestinal inflammatory diseases by oral administration
CN106659755A (zh) 一种处理哺乳动物性功能障碍的方法、药品及药品配方
US20170304204A1 (en) Compositions and methods for increasing the bioavailability of one or more compounds
CN113384705A (zh) 泊洛沙姆修饰的脂质体的制备及在口服药物递送中的应用
CN102872462B (zh) 一种盐酸氨溴索组合物及其制剂
JP2015521633A (ja) ２，２’，６，６’−テトライソプロピル−４，４’−ビフェノール軟カプセル製剤及びその製造方法
JP7301883B2 (ja) Ｈｃ－１１１９製剤及びその製造方法と使用
WO2018037384A1 (fr) Injection sous-cutanée pour réduire le poids corporel et application associée
CN103768071B (zh) 一种治疗糖尿病的口服制剂
Poorani et al. Improving bioavailability of phytochemicals through niosomes
CN107126418A (zh) 供注射用双氯芬酸钠药物组合物及其制备方法
CN102309441A (zh) 一种水飞蓟宾药物组合包装物及其制备方法
CN102293753A (zh) 辅酶q10纳米混悬剂冻干组合物及其制备方法和应用
CN108853017B (zh) 一种雌三醇纳米口服制剂的组方与制备工艺
CN112957481A (zh) 一种难溶性药物包合物、包合方法及盐酸金霉素可溶性粉
CN106806376A (zh) 对乙酰氨基酚和甘草酸或其盐或其衍生物的药物组合物
JP2007326796A (ja) 金コロイドを含有する美白剤およびチロシナーゼ阻害剤
CN109758432A (zh) 一种二氟尼柳肠溶片及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17873709

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27/09/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17873709

Country of ref document: EP

Kind code of ref document: A1